What changes for a practice as more men book aesthetic care

Who this is for

This is for the physician or medical professional who owns a cosmetic surgery, dermatology or injectables practice, and/or the operations lead who sets the price list, books the consults and decides where the marketing budget goes.

Most of the published numbers on male plastic surgery trends are counts: how many injections went into men, how many surgeons say they see men. Fewer describe what a man buys once he is in the practice, what he pays, and how his visit differs from a woman's.

I started with one working assumption: men are less used than women to seeing what aesthetic treatment costs. The evidence below touches it only indirectly.

How much more do men pay per toxin visit than women, and what drives it?

They receive more toxin. Guidepoint Qsight, a medical aesthetics data company that reports from patient transaction records, says men get 10% to 15% more units per visit than women, at the same price per unit, so the extra amount men pay per visit comes entirely from dose¹.

Qsight's measure is average spend per transaction: what a patient paid the practice for one neurotoxin visit, taken from practice records¹. In the third quarter of 2026 to date, men's average was $529, the highest Qsight says it has captured¹. The release does not say whether the $529 covers anything besides the toxin, or which countries its practices are in. The release calls the difference the "Brotox bump"¹.

The size of men's lead has moved around. Qsight puts the male spending premium (how much more men paid per toxin transaction than women, in percent) at nearly 20% in 2022 and under 13% in early 2026¹. In the third quarter of 2026 to date it jumped back to over 16%, which the release calls a sharp reversal¹.

The release does not say how many practices feed Qsight's data or whether that set changed between 2022 and 2026, so the narrowing could come from a changed panel as well as from changed patients¹.

An earlier Qsight cut, reported by American Spa in March 2025, measured something else: what each patient spent across a whole year, on nonsurgical treatments and products together. In 2023, men averaged $1,678 a year against $1,357 for women².

That annual total includes skin-care products and weight-loss treatment, so it answers a different question from the per-visit toxin premium: what a man spends with a practice over a year, all services together^1,2.

Toxin is a smaller part of what men spend at a practice. In a September 2024 report with the advisory firm Skytale, Qsight put neurotoxin at 32% of women's nonsurgical spending and 14% of men's³. Hormone replacement therapy took 19% of men's spending, against 3% of women's³.

Both of Qsight's toxin numbers describe the patient's bill: what the patient paid the practice¹. What the practice pays the manufacturer for each vial is a separate layer, and a supplier rebate changes that cost without changing what the patient sees. In Qsight's transaction records, the price per unit men paid matched the price per unit women paid¹. The higher male bill comes from the number of units.

None of these sources works out what the extra dose does to a practice's own numbers, but the arithmetic is short. A practice that charges patients by the unit collects more from a man who needs 15% more units. It also buys more product from its supplier for him, so what it keeps on each unit (the patient's price per unit minus the practice's cost per unit) stays about the same. A practice that charges patients a flat fee per treatment area collects the same fee from that man and pays the supplier for the extra product itself.

The extra dose also lands in the consult. A per-unit price list shows the price of one unit. A man who needs 10% to 15% more units than the average woman pays a visit total the list never states¹. Unless someone works that total out with him before the injection, he may first see it at checkout.

What share of aesthetic patients are men, by age and region?

Women are still about nine in ten medical spa patients. Skytale, an advisory firm, estimated from its own practice data a shift from 95% women to about 90%³. Aesthetic Record, citing AmSpa's 2024 data, puts women at 89% of medspa patients⁴.

Most surgeons see some men. In the 2024 trends survey of the American Academy of Facial Plastic and Reconstructive Surgery, 92% of member surgeons said they had male patients in their practice⁵. Blepharoplasty (eyelid surgery), rhinoplasty and facelifts were the most common surgeries among those men⁵.

The American Society of Plastic Surgeons counted 593,854 neuromodulator injections for men in its 2024 statistics report⁶. The society says the number rose from the year before but gives no size for that rise, and it prints no share of all neuromodulator patients beside the count⁶. It counts procedures, not patients or dollars.

The same 2026 Aesthetic Record post says practices that market to men report male patient bases growing to about 15% of their total volume, without saying whether volume means patients or visits⁴. It gives no sample, no time period and no starting share for those practices⁴.

A 2022 global survey in Aesthetic Surgery Journal comes at the question from the demand side. It recruited 14,584 "aesthetically conscious" adults aged 21 to 75, and 30% of them were men⁷. It also surveyed 1,315 aesthetic physicians⁷. Those were people already interested in their appearance, and the 30% describes only them.

For an owner, the more useful detail is who the men are. In October 2026 Qsight said Gen X men lead male neurotoxin spending, with millennials close behind¹. The release does not say whether that ranking is by total dollars or by spend per patient.

Region shows up too. Qsight reports that male neurotoxin spending is concentrated in the West, where men "account for a meaningfully higher share of spend than women," and says that gap has widened¹. The release does not say what that share is a share of. The release gives no breakdown below the regional level, so it offers no metro-level picture.

A western practice whose patients are mostly Gen X and millennial matches the age groups and the region where Qsight reports the most male toxin spending¹. Unfortunately, Qsight gives no number for any single practice.

Besides toxin, which services bring men into the practice?

Two of Qsight's categories grew among men: hair restoration and weight-loss treatment^2,8. Both bring men into the practice for something other than a facial injection.

MedEsthetics, reporting Qsight data in 2025, put men's average spend on hair transplant and restoration at $5,335 per visit in 2023, up 14% on 2022⁸. The article calls it the largest category of men's aesthetic spending that year⁸. It does not say whether the $5,335 covers the surgeon's fee, the facility and anesthesia, or only part of the bill. A hair restoration visit and a toxin visit are different purchases, so the two averages are not comparable prices.

Weight-loss treatment took a rising share of men's nonsurgical spending in American Spa's report of Qsight data: 5% in 2022, 13% in 2023 and 17% in 2024 to date². Here "men's nonsurgical spending" means what men paid practices for nonsurgical treatments and products combined. The article ties the rise to the surge in semaglutide prescriptions².

A share that climbs from 5% to 17% in two years changes what men ask a practice for². A man who first comes to the practice for a semaglutide program or a hair consult is already a patient when toxin or skin care comes up. Neither article reports how often those men are cross-sold into toxin or skin care later.

Surgery follows a different pattern. The facial plastic surgeons' survey names eyelid surgery, rhinoplasty and facelifts as men's most common procedures⁵. The plastic surgeons' society says its members are noticing more men asking to refresh their face, and frames the trend as self-care in tough economic times⁶. Neither organization reports what share of a typical surgical practice these men make up.

Among the sources we read, the case for marketing to men at a med spa rests on Aesthetic Record's post. It says men are not walking into most medical spas because those spas are not talking to them, and that practices marketing to men report male patient bases of about 15%⁴. We sell marketing to practices, so we would like that to be true; the post gives nothing a practice could check it against.

The same post cites a 2018 survey, reported by AestheticsPro, in which 1 in 3 American men said they would consider Botox and 1 in 4 said they would spend over $500 on it⁴. That $500 is what men told a survey they would be willing to spend, passed on through two other companies, and the post does not say what "the procedure" included. It is a stated intention, so we do not set it beside Qsight's transaction data.

No source in the set tested which messages or channels bring men to a practice.

What evidence is there on how men react to treatment prices?

No source in the set splits a reaction to price by sex inside a practice. The nearest evidence comes from a skin-care poll and one surgery study.

YouGov polled 1,148 US adult citizens online from April 11 to 15, 2024, about skin care⁹. Asked the most they would spend on a single skin-care product, 9% of women said more than $60, against 2% of men⁹. That is what people said they would pay for one retail product. It is a different layer of price from a treatment visit billed by a practice.

The poll asked about one retail product. It did not ask about treatment prices, so it does not test my working assumption about men and what treatment costs.

A 2024 study in Aesthetic Plastic Surgery reports p = 0.44 for income¹⁰. We have that number as quoted by Perplexity, not from the paper. A p-value that high means the study did not detect an effect of income, which differs from showing that income has none.

If income does not separate people who have surgery from people who do not, cost may weigh as a judgment about value at any income.

What can a practice's own records show about its male patients?

Qsight's numbers are averages across one company's panel of practices^1,2,8. A single practice's booking system already records which service each man booked first, and its billing records hold units per toxin visit by sex.

Qsight's 2024 report found men and women close on spend and visits, and furthest apart on retention: its practice retention rate for 2022 to 2023 was 53% for women and 49% for men³. A practice can work out the same rate from its own records.

Those records would show whether hair restoration, weight-loss treatment or toxin brings men to that practice, and whether its male patients take the 10% to 15% extra dose Qsight reports¹.

On a per-area price list, any extra dose comes out of the practice's margin. On a per-unit list, it lands on a visit total the patient does not see until someone adds it up.

About this review

We read 10 published sources in October 2026: three vendor-published pieces, two trade press articles, three industry surveys (two from medical societies and one YouGov poll), and two peer-reviewed studies. Each number is labeled by who produced it, and vendor numbers are reported as the vendor's claims.

Four of the ten report Guidepoint Qsight's transaction data (Qsight's own release, its report with Skytale, American Spa and MedEsthetics), so most of the spending numbers trace back to one company's panel. None of the three states how many practices that panel includes or how its makeup has changed over time.

The Aesthetic Plastic Surgery number is as quoted by Perplexity, so only its income finding is used. The Aesthetic Surgery Journal survey and the YouGov poll were read on their own pages, with their stated sample sizes and dates. The plastic surgeons' society count comes with no share of patients and no percentage change, and no source in the set gives a male share of patients from a defined sample.

Fractional Aesthetics is a growth strategy practice for aesthetic medical businesses.